Page 118 - Read Online

Page 10 of 14 Chia et al. Hepatoma Res 2019;5:9 I http://dx.doi.org/10.20517/2394-5079.2018.112

Gastroenterol 2015;21:10573-83.
7. Mizejewski GJ. Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. Exp Biol Med
2001;226:377-408.
8. Gitlin D, Perricelli A, Gitlin JD. The presence of serum alphafetoprotein in sharks and its synthesis by fetal gastrointestinal tract and
liver. Comp BiochemPhysiol B 1973;46:207-15.
9. Debruyne EN, Delanghe JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and
applications. Clin Chim Acta 2008;395:19-26.
10. Chayvialle JA, Ganguli PC. Radioimmunoassay of alpha-fetoprotein in human plasma. Lancet 1973;1:1355-7.
11. Waldmann TA, McIntire KR. The use of a radioimmunoassay for alpha-fetoprotein in the diagnosis of malignancy. Cancer
1974;34:1510-5.
12. Chayvialle JA, Ganguli PC. Radioimmunoassay of alpha-fetoprotein in human plasma. Lancet 1973;1:1355-7.
13. Lederle FA, Pocha C. Screening for liver cancer: the rush to judgment. Ann Intern Med 2012;156:387-9.
14. Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, et al. Screening for liver cancer: results of a randomized controlled trial in Qidong,
China. J Med Screen 2003;10:204-9.
15. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol
2004;130:417-22.
16. Muguti G, Tait N, Richardson A, Little JM. Alpha-fetoprotein expression in hepatocellular carcinoma: a clinical study. J Gastroenterol
Hepatol 1992;7:374-8.
17. Chu CW, Hwang SJ, Luo JC, Lai CR, Tsay SH, et al. Clinical, virologic, and pathologic significance of elevated serum alpha-
fetoprotein levels in patients with chronic hepatitis C. J Clin Gastroenterol 2001;32:240-4.
18. Talerman A, Haije WG, Baggerman L. Serum alphafetoprotein (AFP) in patients with germ cell tumors of the gonads and extragonadal
sites: correlation between endodermal sinus (yolk sac) tumor and raised serum AFP. Cancer 1980;46:380-5.
19. Ucar E, Semerci E, Ustun H, Yetim T, Huzmeli C, et al. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in
gastric cancer. Adv Ther 2008;25:1075-84.
20. Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta 2001;313:15-9.
21. Sterling RK, Jeffers L, Gordon F, Venook AP, Reddy KR, et al. Utility of Lens culinaris agglutinin-reactive fraction of alpha-
fetoprotein and des-gammacarboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin
Gastroenterol Hepatol 2009;7:104-13.
22. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectinbound
alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009;137:110-8.
23. Kagebayashi C, Yamaguchi I, Akinaga A, Kitano H, Yokoyama K, et al. Automated immunoassay system for AFP-L3% using on-chip
electrokinetic reaction and separation by affinity electrophoresis. Anal Biochem 2009;388:306-11.
24. Reichl P, Fang M, Starlinger P, Staufer K, Nenutil R, et al. Multicenter analysis of soluble Axl reveals diagnostic value for very early
stage hepatocellular carcinoma. Int J Cancer 2015;137:385-94.
25. Zhang Z, Lee JC, Lin L, Olivas V, Au V, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung
cancer. Nat Genet 2012;44:852-60.
26. Rankin EB, Fuh KC, Taylor TE, Krieg AJ, Musser M, et al. AXL is an essential factor and therapeutic target for metastatic ovarian
cancer. Cancer Res 2010;70:7570-9.
27. Dunne PD, McArt DG, Blayney JK, Kalimutho M, Greer S, et al. AXL is a key regulator of inherent and chemotherapy-induced
invasion and predicts a poor clinical outcome in early-stage colon cancer. Clin Cancer Res 2014;20:164-75.
28. D’Alfonso TM, Hannah J, Chen Z, Liu Y, Zhou P, et al. Axl receptor tyrosine kinase expression in breast cancer. J Clin Pathol
2014;67:690-6.
29. Song X, Wang H, Logsdon CD, Rashid A, Fleming JB, et al. Overexpression of receptor tyrosine kinase Axl promotes tumor cell
invasion and survival in pancreatic ductal adenocarcinoma. Cancer 2011;117:734-43.
30. Varnum BC, Young C, Elliott G, Garcia A, Bartley TD, et al. Axl receptor tyrosine kinase stimulated by the vitamin K-dependent
protein encoded by growth-arrest-specific gene 6. Nature 1995;373:623-6.
31. Fridell YW, Jin Y, Quilliam LA, Burchert A, McCloskey P, et al. Differential activation of the Ras/extracellularsignal-regulated
protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase. Mol Cell Biol
1996;16:135-45.
32. Tai KY, Shieh YS, Lee CS, Shiah SG, Wu CW. Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-
kappaB and Brg-1. Oncogene 2008;27:4044-55.
33. Ruan GX, Kazlauskas A. Axl is essential for VEGF-A-dependent activation of PI3K/Akt. EMBO J 2012;31:1692-703.
34. Paccez JD, Vasques GJ, Correa RG, Vasconcellos JF, Duncan K, et al. The receptor tyrosine kinase Axl is an essential regulator of
prostate cancer proliferation and tumor growth and represents a new therapeutic target. Oncogene 2013;32:689-98.
35. Hong CC1, Lay JD, Huang JS, Cheng AL, Tang JL, et al. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and
overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett 2008;268:314-24.
36. Neubauer A, Fiebeler A, Graham DK, O’Bryan JP, Schmidt CA, et al. Expression of axl, a transforming receptor tyrosine kinase, in
normal and malignant hematopoiesis. Blood 1994;84:1931-41.
37. Shieh YS, Lai CY, Kao YR, Shiah SG, Chu YW, et al. Expression of axl in lung adenocarcinoma and correlation with tumor
progression. Neoplasia 2005;7:1058-64.
38. Li N, Liu Z, Zhang Y, Chen Q, Liu P, et al. Mice lacking Axl and Mer tyrosine kinase receptors are susceptible to experimental
autoimmune orchitis induction. Immunol Cell Biol 2015;93:311-20.
39. Weinger JG, Brosnan CF, Loudig O, Goldberg MF, Macian F, et al. Loss of the receptor tyrosine kinase Axl leads to enhanced